HR+/HER2- Metastatic Breast Cancer: Future Directions in Care
Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
EP: 1.What to Test for in Patients With Early- or Late-Stage Breast Cancer
EP: 2.Novel Testing Methodologies in Breast Cancer Management
EP: 3.What is the Role of Germline Testing in Patients With Breast Cancer?
EP: 4.Patient Case 1: Mutated ESR1 in HR+/HER2- Metastatic Breast Cancer
EP: 5.Optimal ESR1 Testing Strategies in HR+/HER2- Metastatic Breast Cancer
EP: 6.HR+/HER2- Metastatic Breast Cancer: Impact of ESR1 Mutation on Treatment
EP: 7.Trial Data: 2L Therapy After ET + CDK4/6i in HR+/HER2- Metastatic Breast Cancer
EP: 8.Considerations for Selecting and Sequencing Therapy in HR+/HER2- mBC
EP: 9.EMERALD: Elacestrant in Relapsed/Refractory HR+/HER2- mBC
EP: 10.Relapsed/Refractory HR+/HER2- mBC: Real-World Applications of the EMERALD Trial
EP: 11.Patient Case 2: Unmutated HR+/HER2- Metastatic Breast Cancer
EP: 12.TROPiCS-02: Sacituzumab Govitecan in Relapsed/Refractory HR+/HER2- mBC
EP: 13.DESTINY-Breast04: T-DXd in HER2-Low Metastatic Breast Cancer
EP: 14.Evolving Role of Antibody Drug Conjugates in Metastatic Breast Cancer
EP: 15.HR+/HER2- Metastatic Breast Cancer: Future Directions in Care
Transcript:
Joyce A. O’Shaughnessy, MD: I’d like to thank you for being here today.… And I think…we want to front-load our endocrine therapy as much as we possibly can. We are going to get more and more tools to both understand mechanisms of resistance that are coming both at the tissue level and in the blood ctDNA [circulating tumor DNA] level and understand, I hope, with the help of you all there at Memorial [Sloan Kettering] and your tumor board, to understand the role of co-mutations and serial evolution of different clones coming up. And it’s going to be a lot of very important work over a lot of years to understand how to best help patients get the most durable benefit in endocrine therapy. Right now, we’re fortunate to be able to find PIK3CA mutations. Hopefully, soon, AKT mutations, PTEN loss. Or maybe we won’t even have to find those. We’ll be able to give capivasertib to everybody who’s progressing on CDK [inhibitors].… And then ESR1 mutations. It’s both good news but frustrating. Good news is it’s still an ER [estrogen receptor]-dependent breast cancer. Bad news is our traditional agents really don’t work well. But thankfully, we have a new agent that really can give the patient the opportunity to get a very durable response. About 25% of the patients going out about a year, 23%, I think, to be exact.… So we’ve got to find those ESR1 mutations. So thank you so much for your really thoughtful, comprehensive discussions and analysis. And I really want to thank our viewing audience as well and thank Targeted Oncology™ for putting together this tumor board so we can get together. I hope this is a valuable use of your time and, most importantly, that this will [provide] some practical application to your practice. Thank you all very much.
Transcript is AI-generated and edited for clarity and readability.
Elacestrant-Abemaciclib Combo Shows Promise for Breast Cancer
September 19th 2024The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine therapy and another CDK4/6 inhibitor.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Neoadjuvant and Adjuvant Pembrolizumab Extends Survival in Early-Stage TNBC
September 15th 2024In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to improvements in overall survival among patients with triple-negative breast cancer.
Read More
